Vivid Seats Inc. Class A SEAT 深 滬
等待開盤 03-26 09:30:00 美东时间
5.30
-0.190
-3.46%
華盛通- 最 高5.69
- 今 開5.57
- 成交量 7.85万股
- 最 低 5.25
- 昨 收 5.49
- 總市值 5705.87万
- 52周最高 60.20
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 5.06
- 委 比 0.00%
- 總股本 1076.58万
- 歷史最高 287.00
- 量 比 0.51
- 振 幅 8.01%
- 歷史最低 5.06
- 每 手 1
- 風險率 16.48%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 韦德布什升美光科技目标价升至500美元，维持"跑赢大市"评级
今日重点评级关注：Piper Sandler：维持Allogene疗法"超配"评级，目标价从7美元升至8美元；B. Riley证券：维持Oncology Institute"买入"评级，目标价从6美元升至8美元
03-16 18:19
Vivid Seats Analysts Cut Their Forecasts After Q4 Loss
Vivid Seats (NASDAQ:SEAT) reports Q4 loss of $428.7M, revenue down 37% to $126.8M. Shares up 4.4% to $5.90. Analysts adjust price targets.
03-14 17:18
Benchmark Maintains Buy on Vivid Seats, Lowers Price Target to $10
Benchmark analyst Daniel L. Kurnos maintains Vivid Seats (NASDAQ:SEAT) with a Buy and lowers the price target from $18 to $10.
03-13 20:45
Earnings Scheduled For March 12, 2026
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is likel...
03-12 19:11
11 Communication Services Stocks Moving In Monday's Intraday Session
Gainers Star Fashion Culture (NASDAQ:STFS) shares increased by 39.2% to $0.11 ...
02-24 01:05
美股大行评级 | 潜在涨幅113%！麦格理首予小马智行“跑赢大市"评级目标价29美元；Roth Capital下调好市多至"卖出"，目标价从906美元降至769美元
今日重点评级关注：HC Wainwright & Co.：维持BioCryst Pharma"买入"评级，目标价从30美元升至32美元；TD Cowen：上调Milestone Pharmaceuticals评级至"买入"，目标价8美元
2025-12-16 09:36
Citigroup Maintains Neutral on Vivid Seats, Lowers Price Target to $8.5
Citigroup analyst Jason Bazinet maintains Vivid Seats (NASDAQ:SEAT) with a Neutral and lowers the price target from $10 to $8.5.
2025-12-16 05:24
12 Communication Services Stocks Moving In Wednesday's Pre-Market Session
Gainers Arena Group Holdings (AMEX:AREN) shares moved upwards by 11.0% to $5.2...
2025-11-12 20:05
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 10:22
